Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

R Kodera, K Shikata, T Takatsuka, K Oda… - Biochemical and …, 2014 - Elsevier
R Kodera, K Shikata, T Takatsuka, K Oda, S Miyamoto, N Kajitani, D Hirota, T Ono, HK Usui…
Biochemical and Biophysical Research Communications, 2014Elsevier
Abstract Introduction Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs in
patients with type 2 diabetes. In our previous study, we showed that glucagon-like peptide-1
(GLP-1) receptor agonist has reno-protective effects through anti-inflammatory action. The
mechanism of action of DPP-4 inhibitor is different from that of GLP-1 receptor agonists. It is
not obvious whether DPP-4 inhibitor prevents the exacerbation of diabetic nephropathy
through anti-inflammatory effects besides lowering blood glucose or not. The purpose of this …
Introduction
Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs in patients with type 2 diabetes. In our previous study, we showed that glucagon-like peptide-1 (GLP-1) receptor agonist has reno-protective effects through anti-inflammatory action. The mechanism of action of DPP-4 inhibitor is different from that of GLP-1 receptor agonists. It is not obvious whether DPP-4 inhibitor prevents the exacerbation of diabetic nephropathy through anti-inflammatory effects besides lowering blood glucose or not. The purpose of this study is to clarify the reno-protective effects of DPP-4 inhibitor through anti-inflammatory actions in the early diabetic nephropathy.
Materials and methods
Five-week-old male Sprague–Dawley (SD) rats were divided into three groups; non-diabetes, diabetes and diabetes treated with DPP-4 inhibitor (PKF275-055; 3 mg/kg/day). PKF275-055 was administered orally for 8 weeks.
Results
PKF275-055 increased the serum active GLP-1 concentration and the production of urinary cyclic AMP. PKF275-055 decreased urinary albumin excretion and ameliorated histological change of diabetic nephropathy. Macrophage infiltration was inhibited, and inflammatory molecules were down-regulated by PKF275-055 in the glomeruli. In addition, nuclear factor-κB (NF-κB) activity was suppressed in the kidney.
Conclusions
These results indicate that DPP-4 inhibitor, PKF275-055, have reno-protective effects through anti-inflammatory action in the early stage of diabetic nephropathy. The endogenous biological active GLP-1 might be beneficial on diabetic nephropathy besides lowering blood glucose.
Elsevier